In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Turns COVID-19 Crisis Into A Global Health Care Opportunity

China's ability to push back digital boundaries position it well in the ongoing transformation of health care delivery

Executive Summary

Another important step has been taken under the Healthy China initiative, with the implementation on June 1 of a basic law on access to health care. This provides additional tailwind for a health system that appeared to efficiently contain its coronavirus outbreak and is now making further structural improvements.

You may also be interested in...



Device Week, 7 August 2020: Brexit, COVID-19 & NHS Reform Augur Big 12 Months For UK Medtech

In this Device Week, Ashley Yeo asks PB Consulting managing director Dan Jones about the adjustments needed by UK medtechs as they face a confluence of change brought about by Brexit, COVID-19 and NHS reform, at a time when the MHRA is also coming under increased scrutiny. 

Carlo Rivis: Know Your Own Value In Bringing Disruptive Innovation To Market

Entrepreneur Carlo Rivis, one of In Vivo’s Rising Leaders, brought his disruptive innovation approaches to in-silico trials and digital avatar developer Computational Life, and now he is doing the same at Innovation Discovery.

Medtechs’ View Of UK Brexit Deal: More Certainty, But Still No Detail

COVID-19 is of no lesser importance to the UK medtech industry, but attention is now refocusing on Brexit, future regulation and trade deals.

Topics

UsernamePublicRestriction

Register

LL043097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel